457 related articles for article (PubMed ID: 35924241)
21. Serine protease inhibitor Kazal type 1 (SPINK1) promotes proliferation, migration, invasion and radiation resistance in rectal cancer patients receiving concurrent chemoradiotherapy: a potential target for precision medicine.
Chen YT; Tseng TT; Tsai HP; Kuo SH; Huang MY; Wang JY; Chai CY
Hum Cell; 2022 Nov; 35(6):1912-1927. PubMed ID: 36053457
[TBL] [Abstract][Full Text] [Related]
22. MAPK inhibitors induce serine peptidase inhibitor Kazal type 1 (SPINK1) secretion in BRAF V600E-mutant colorectal adenocarcinoma.
Räsänen K; Dang KX; Mustonen H; Ho TH; Lintula S; Koistinen H; Stenman UH; Haglund C; Stenman J
Mol Oncol; 2018 Feb; 12(2):224-238. PubMed ID: 29193645
[TBL] [Abstract][Full Text] [Related]
23. Downregulation of phosphoserine phosphatase potentiates tumor immune environments to enhance immune checkpoint blockade therapy.
Peng ZP; Liu XC; Ruan YH; Jiang D; Huang AQ; Ning WR; Jiang ZZ; Zheng L; Wu Y
J Immunother Cancer; 2023 Feb; 11(2):. PubMed ID: 36849198
[TBL] [Abstract][Full Text] [Related]
24. Targeting MMP9 in CTNNB1 mutant hepatocellular carcinoma restores CD8
Cai N; Cheng K; Ma Y; Liu S; Tao R; Li Y; Li D; Guo B; Jia W; Liang H; Zhao J; Xia L; Ding ZY; Chen J; Zhang W
Gut; 2024 May; 73(6):985-999. PubMed ID: 38123979
[TBL] [Abstract][Full Text] [Related]
25. Combination of AFP vaccine and immune checkpoint inhibitors slows hepatocellular carcinoma progression in preclinical models.
Lu X; Deng S; Xu J; Green BL; Zhang H; Cui G; Zhou Y; Zhang Y; Xu H; Zhang F; Mao R; Zhong S; Cramer T; Evert M; Calvisi DF; He Y; Liu C; Chen X
J Clin Invest; 2023 Jun; 133(11):. PubMed ID: 37040183
[TBL] [Abstract][Full Text] [Related]
26. Immune-related long noncoding RNA signature for predicting survival and immune checkpoint blockade in hepatocellular carcinoma.
Zhang Y; Zhang L; Xu Y; Wu X; Zhou Y; Mo J
J Cell Physiol; 2020 Dec; 235(12):9304-9316. PubMed ID: 32330311
[TBL] [Abstract][Full Text] [Related]
27. Identification of prognostic markers for hepatocellular carcinoma based on the epithelial-mesenchymal transition-related gene BIRC5.
Xu R; Lin L; Zhang B; Wang J; Zhao F; Liu X; Li Y; Li Y
BMC Cancer; 2021 Jun; 21(1):687. PubMed ID: 34112092
[TBL] [Abstract][Full Text] [Related]
28. Identification and Exploration of Serine Peptidase Inhibitor Kazal Type I (SPINK1) as a Potential Biomarker Correlated with the Progression of Non-Small Cell Lung Cancer.
Li D; Zhang X; Ding Z; Ai R; Shi L; Wang Z; He Q; Dong Y; Zhu Y; Ouyang W; He Y
Cell Biochem Biophys; 2022 Dec; 80(4):807-818. PubMed ID: 36194314
[TBL] [Abstract][Full Text] [Related]
29. Hepatocellular Carcinoma Cells Up-regulate PVRL1, Stabilizing PVR and Inhibiting the Cytotoxic T-Cell Response via TIGIT to Mediate Tumor Resistance to PD1 Inhibitors in Mice.
Chiu DK; Yuen VW; Cheu JW; Wei LL; Ting V; Fehlings M; Sumatoh H; Nardin A; Newell EW; Ng IO; Yau TC; Wong CM; Wong CC
Gastroenterology; 2020 Aug; 159(2):609-623. PubMed ID: 32275969
[TBL] [Abstract][Full Text] [Related]
30. Identification of chromatin organization-related gene signature for hepatocellular carcinoma prognosis and predicting immunotherapy response.
Chen J; Chen X; Li T; Wang L; Lin G
Int Immunopharmacol; 2022 Aug; 109():108866. PubMed ID: 35691273
[TBL] [Abstract][Full Text] [Related]
31. High expression of PDZ-binding kinase is correlated with poor prognosis and immune infiltrates in hepatocellular carcinoma.
Mu W; Xie Y; Li J; Yan R; Zhang J; Liu Y; Fan Y
World J Surg Oncol; 2022 Jan; 20(1):22. PubMed ID: 35065633
[TBL] [Abstract][Full Text] [Related]
32. Identification of immune-related lncRNA signature for predicting immune checkpoint blockade and prognosis in hepatocellular carcinoma.
Xu Q; Wang Y; Huang W
Int Immunopharmacol; 2021 Mar; 92():107333. PubMed ID: 33486322
[TBL] [Abstract][Full Text] [Related]
33. [Differential analysis of gene expression profiles in hepatocellular carcinoma patients with high and low levels of alpha-fetoprotein].
Wang XJ; Shen RF; Wang X; Wang YR; Xiao T
Zhonghua Zhong Liu Za Zhi; 2020 May; 42(5):396-402. PubMed ID: 32482029
[No Abstract] [Full Text] [Related]
34. Uncoupling immune trajectories of response and adverse events from anti-PD-1 immunotherapy in hepatocellular carcinoma.
Chuah S; Lee J; Song Y; Kim HD; Wasser M; Kaya NA; Bang K; Lee YJ; Jeon SH; Suthen S; A'Azman S; Gien G; Lim CJ; Chua C; Hazirah SN; Lee HK; Lim JQ; Lim TKH; Yeong J; Chen J; Shin EC; Albani S; Zhai W; Yoo C; Liu H; Choo SP; Tai D; Chew V
J Hepatol; 2022 Sep; 77(3):683-694. PubMed ID: 35430299
[TBL] [Abstract][Full Text] [Related]
35. High expression of serine protease inhibitor kazal type 1 predicts poor prognosis and promotes the progression and invasion of oral tongue squamous cell carcinoma.
Wang S; Sun Y; Shao D; Pan Y; Gao X; Zhao P; Liu Q; Shang G; Shang W; Fu Z; Sun Y
Arch Oral Biol; 2024 Aug; 164():106003. PubMed ID: 38781741
[TBL] [Abstract][Full Text] [Related]
36. Androgen receptor affects the response to immune checkpoint therapy by suppressing PD-L1 in hepatocellular carcinoma.
Jiang G; Shi L; Zheng X; Zhang X; Wu K; Liu B; Yan P; Liang X; Yu T; Wang Y; Cai X
Aging (Albany NY); 2020 Jun; 12(12):11466-11484. PubMed ID: 32579541
[TBL] [Abstract][Full Text] [Related]
37. Upregulation of Stress-Induced Protein Kinase CK1 Delta is associated with a Poor Prognosis for patients with Hepatocellular Carcinoma.
Zhang H; Qiu C; Zeng H; Zhu W; Lyu W; Lao X
Genet Test Mol Biomarkers; 2021 Jul; 25(7):504-514. PubMed ID: 34280005
[No Abstract] [Full Text] [Related]
38. Serum small extracellular vesicle-derived LINC00853 as a novel diagnostic marker for early hepatocellular carcinoma.
Kim SS; Baek GO; Ahn HR; Sung S; Seo CW; Cho HJ; Nam SW; Cheong JY; Eun JW
Mol Oncol; 2020 Oct; 14(10):2646-2659. PubMed ID: 32525601
[TBL] [Abstract][Full Text] [Related]
39. Anti-BIRC5 autoantibody serves as a valuable biomarker for diagnosing AFP-negative hepatocellular carcinoma.
Li Q; Liu H; Wang H; Xiong W; Dai L; Zhang X; Wang P; Ye H; Shi J; Fang Z; Wang K
PeerJ; 2024; 12():e17494. PubMed ID: 38832035
[TBL] [Abstract][Full Text] [Related]
40. Oxaliplatin induces immunogenic cell death in hepatocellular carcinoma cells and synergizes with immune checkpoint blockade therapy.
Zhu H; Shan Y; Ge K; Lu J; Kong W; Jia C
Cell Oncol (Dordr); 2020 Dec; 43(6):1203-1214. PubMed ID: 32797385
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
